Carver College of Medicine Events
Women In Micro & Immuno Coffee Hour
Monday, January 13, 11:00am to Monday, December 8, 2025 12:00pm
Join us for the Women in Micro & Immuno Coffee Hour. It is the monthly coffee hour on the second Monday of the month from 11 a.m. to noon in 1289 CBRB. Enjoy coffee, pastries and contribute to the discussion!
This is open to ALL — students, staff, postdocs, and faculty interested in promoting women in science.
Speakers change monthly. Contact: jessica-tucker@uiowa.edu for details.
Women In Micro & Immuno Coffee Hour
Monday, March 10, 2025 11:00am to Monday, February 2, 2026 11:00am
Join us for the Women in Micro & Immuno Coffee Hour. It is the monthly coffee hour on the second Monday of the month from 11 a.m. to noon in 1289 CBRB. Enjoy coffee, pastries and contribute to the discussion!
This is open to ALL — students, staff, postdocs, and faculty interested in promoting women in science.
Speakers change monthly. Contact: jessica-tucker@uiowa.edu for details.

ACB Seminar Series - Amelia Hurley-Novatny & Tate Neff
Wednesday, April 2, 2025 9:30am to 10:30am
Amelia Hurley-Novatny, a MSTP student from the Li Lab will present a seminar titled "Intra-Articular Injection of Matrix-Bound Nanovesicles Attenuates Development of Post-Traumatic Osteoarthritis in a Mouse Model”Tate Neff, a CDB student from the Yang Lab will present a seminar titled "The Role of Micropeptide in BNLN in CFRD”

2025 Celebration of Excellence and Achievement Among Women
Wednesday, April 2, 2025 3:30pm to 5:00pm
Join us for our awards ceremony and reception, honoring the giants who blazed the trail before us celebrating the incredible accomplishments crafted over the past year!
Refreshments and social time will begin at 3:30 p.m., and the award celebration will begin at 4 p.m.
This event is free and open to the public.
This event recognizes the recipients for the following awards:
May Brodbeck Distinguished Achievement Award for Faculty
Susan C. Buckley Distinguished Achievement Award for Staff...

Biochemistry and Molecular Biology Seminar: Dr. Edward H. Egelman
Thursday, April 3, 2025 10:30am to 11:20am
This event is open to the public.
Using Cryo-EM to Understand Evolution
Edward H. Egelman, PhD
Harrison Distinguished Professor,
Department of Biochemistry and Molecular Genetics
Professor of Molecular Physiology and Biological Physics
University of Virginia
Egelman Lab | https://egelmanlab.org/
Recent Articles from the University of Iowa
Enhancing access to nephrology care: telenephrology dashboard optimization via human-centered design
Tuesday, April 1, 2025
CONCLUSION: The Telenephrology Dashboard was developed using a Human-Centered Design approach to improve remote nephrology consultations. Future efforts will focus on evaluating its impact on user satisfaction, referring clinician satisfaction, access to nephrology care, and patient care outcomes.
Type I interferons induce guanylate-binding proteins and lysosomal defense in hepatocytes to control malaria
Tuesday, April 1, 2025
Plasmodium parasites undergo development and replication within hepatocytes before infecting erythrocytes and initiating clinical malaria. Although type I interferons (IFNs) are known to hinder Plasmodium infection within the liver, the underlying mechanisms remain unclear. Here, we describe two IFN-I-driven hepatocyte antimicrobial programs controlling liver-stage malaria. First, oxidative defense by NADPH oxidases 2 and 4 triggers a pathway of lysosomal fusion with the parasitophorous vacuole...
A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Thursday, March 27, 2025
Immune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the...
Highly Variable Aggregation and Glycosylation Profiles and Their Roles in Immunogenicity to Protein-Based Therapeutics
Wednesday, March 26, 2025
Production of antibodies against protein-based therapeutics (e.g., monoclonal antibodies (mAbs)) by a recipient's immune system can vary from benign symptoms to chronic neutralization of the compound, and in rare cases, a lethal cytokine storm. One critical factor that can induce or contribute to an anti-drug antibody (ADA) response is believed to be the presence of aggregated proteins in protein-based therapeutics. There is a high level of variability in the aggregation of different proteins,...
Transcriptional repressor Capicua is a gatekeeper of cell-intrinsic interferon responses
Tuesday, March 25, 2025
Early detection of viral infection and rapid activation of host antiviral defenses through transcriptional upregulation of interferons (IFNs) and IFN-stimulated genes (ISGs) are critical for controlling infection. However, aberrant production of IFN in the absence of viral infection leads to auto-inflammation and can be detrimental to the host. Here, we show that the DNA-binding transcriptional repressor complex composed of Capicua (CIC) and Ataxin-1 like (ATXN1L) binds to an 8-nucleotide motif...
CFTR negatively reprograms Th2 cell responses and CFTR potentiation restrains allergic airway inflammation
Tuesday, March 25, 2025
Type 2 inflammatory diseases are common in cystic fibrosis (CF) including asthma, sinusitis, and allergic bronchopulmonary aspergillosis. CD4+ T helper 2 (Th2) cells promote these diseases through secretion of IL-4, IL-5, and IL-13. Whether the cystic fibrosis transmembrane conductance regulator (CFTR), the mutated protein in CF, has a direct effect on Th2 development is unknown. Using murine models of CFTR deficiency and human CD4+ T cells, we show CD4+ T cells expressed Cftr transcript and...
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
Monday, March 24, 2025
Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib is an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor tyrosine kinase associated with poor prognosis, chemotherapy resistance and decreased antitumor immune response. We report bemcentinib monotherapy and bemcentinib+low-dose cytarabine combination therapy arms from the completed BerGenBio-funded open-label Phase 1/2b...
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age
Wednesday, March 19, 2025
Seasonal influenza continues to cause significant morbidity and mortality, particularly for the elderly and immunocompromised. Current licensed influenza vaccines provide only partial protection even for immunocompetent hosts. Vaccine adjuvants can improve the magnitude and breadth of immune responses and there is considerable interest in identifying new adjuvants that can improve immune responses to seasonal influenza vaccines. This phase I, randomized, double-blind trial evaluated the safety...
Evidence of Varicella Zoster Virus Reactivation in Children With Arterial Ischemic Stroke: Results of the VIPS II Study
Tuesday, March 18, 2025
CONCLUSIONS: One in 10 patients with childhood AIS had recent, asymptomatic VZV reactivation. In a vaccinated population, VZV may continue to play a modest role in childhood stroke pathogenesis.
Subacute exposure of male adolescent rats to 2,2',5,5'-tetrachlorobiphenyl-4-ol via a polymeric implant causes gene expression changes in the brain and metabolomic disruption in serum
Monday, March 17, 2025
Polychlorinated biphenyls (PCBs) remain an environmental health concern due to their persistence and ongoing release from legacy and emerging sources. 2,2',5,5'-Tetrachlorobiphenyl (PCB52), a PCB congener frequently detected in the environment and human blood, is oxidized to 2,2',5,5'-tetrachlorobiphenyl-4-ol (4-52). The neurotoxicity of this hydroxylated (OH-PCB) metabolite remains poorly characterized. In this study, we exposed 4-week-old male Sprague Dawley rats to 4-52 via a polymeric...